Nifekalant

Nifekalant (INN) is a class III antiarrhythmic agent approved in Japan for the treatment of arrhythmias and ventricular tachycardia.[1] It has the brand name Shinbit.

Nifekalant
Clinical data
AHFS/Drugs.comInternational Drug Names
Routes of
administration		IV
ATC code
  • none
Legal status
Legal status
  • In general: ℞ (Prescription only)
Identifiers
  • 6-[(2-{(2-hydroxyethyl)[3-(4-nitrophenyl)propyl]amino}ethyl)amino]-1,3-dimethylpyrimidine-2,4(1H,3H)-dione
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC19H27N5O5
Molar mass405.455 g·mol−1
3D model (JSmol)
  • Cn1c(NCCN(CCO)CCCc2ccc([N+](=O)[O-])cc2)cc(=O)n(C)c1=O
  • InChI=1S/C19H27N5O5/c1-21-17(14-18(26)22(2)19(21)27)20-9-11-23(12-13-25)10-3-4-15-5-7-16(8-6-15)24(28)29/h5-8,14,20,25H,3-4,9-13H2,1-2H3
  • Key:OEBPANQZQGQPHF-UHFFFAOYSA-N
  (verify)

References
  1. Oyabe A, Sano H (February 2002). "Pharmacological and clinical profile of nifekalant (shinbit injection), a class III antiarrhythmic drug". Nippon Yakurigaku Zasshi. 119 (2): 103–9. doi:10.1254/fpj.119.103. PMID 11862758.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.